CD11c+ and CD123+ dendritic cell subsets in peripheral blood of lung cancer patients.

Dendritic cells (DCs) play a central role in antitumor immune responses. Recent studies however have emphasized an immunosuppressive tumor influence on DCs in various types of cancer. We evaluated the percentages of myeloid and plasmacytoid related DCs in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Myeloid CD11c+ DCs (mDC) and plasmacytoid CD123+ DCs (pDC) cells were assessed by Flowcytometry in peripheral blood of twenty untreated lung cancer patients (13 NSCLC and 7 SCLC) and 15 healthy subjects. Lower percentages of pDCs and mDCs were found in patient with NSCLC and SCLC as compared to controls, with significant value only between NSCLC patients and controls (P= 0.001and P=0.000 respectively). The percentages of pDCs and mDCs subsets were significantly lower in patient with SCLC than NSCLC (P=0.013 and P=0.005 for pDCs and mDCs respectively). Our results suggest that NSCLC and SCLC might hamper the maturation of DCs, thus escaping an efficient immune response.